Table 1.
Significantly enriched pathways in tumor tissue
| No | Pathway | P-value | FDR P-value |
|---|---|---|---|
| 1 | Cell adhesion_ECM remodeling | 2.76–07 | 0.0001247 |
| 2 | Cell adhesion_Chemokines and adhesion | 1.06–05 | 0.0024 |
| 3 | Immune response_Antigen presentation by MHC class II | 4.31–05 | 0.006169 |
| 4 | Cell adhesion_Endothelial cell contacts by non-junctional mechanisms | 5.47-05 | 0.006169 |
| 5 | Cell adhesion_Integrin-mediated cell adhesion and migration | 1.93–04 | 0.01743 |
| 6 | LRRK2 in neurons in Parkinson’s disease | 2.68–04 | 0.02018 |
| 7 | Cell adhesion_Plasmin signaling | 3.57–04 | 0.02275 |
| 8 | Development_Hedgehog and PTH signaling pathways in bone and cartilage development | 4.08-04 | 0.02275 |
| 9 | Cytoskeleton remodeling_Cytoskeleton remodeling | 4.54-04 | 0.02275 |
| 10 | Transport_Macropinocytosis regulation by growth factors | 8.59-04 | 0.03225 |
| 11 | Development_Leptin signaling via JAK/STAT and MAPK cascades | 9.20-04 | 0.03225 |
| 12 | Development_Regulation of epithelial-to-mesenchymal transition (EMT) | 9.34-04 | 0.03225 |
| 13 | Cell adhesion_Cadherin-mediated cell adhesion | 1.07–03 | 0.03225 |
| 14 | Immune response_IL-10 signaling pathway | 1.07–03 | 0.03225 |
| 15 | Development_S1P2 and S1P3 receptors in cell proliferation and differentiation | 1.07–03 | 0.03225 |
| 16 | Regulation of degradation of deltaF508 CFTR in CF | 1.24–03 | 0.035 |
| 17 | Development_Slit-Robo signaling | 1.86–03 | 0.04935 |
Table shows significantly enriched pathways (FDR P-value < 0.05) in tumor tissue based on identified differentially expressed genes. Common up- and downregulated genes were identified upon comparing tumor tissue to both adjacent and skin tissue. Pathway names, raw P-value, and FDR P-value are given.